Andrew McLean - Camurus AB VP Counsel
| CAMX Stock | SEK 598.00 5.00 0.84% |
Insider
Andrew McLean is VP Counsel of Camurus AB
| Age | 58 |
| Phone | 46 4 62 86 57 30 |
| Web | https://www.camurus.com |
Camurus AB Management Efficiency
The company has return on total asset (ROA) of 0.0146 % which means that it generated a profit of $0.0146 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0317 %, meaning that it generated $0.0317 on every $100 dollars invested by stockholders. Camurus AB's management efficiency ratios could be used to measure how well Camurus AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christer Mller | BioArctic AB | 64 | |
| Harald Borgeke | BioArctic AB | N/A | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Pablo Mora | Swedish Orphan Biovitrum | 55 | |
| Gunilla Andersson | BioArctic AB | 62 | |
| Pr Lannfelt | BioArctic AB | 74 | |
| Pr MD | Oncopeptides AB | N/A | |
| Frida Lekander | BioArctic AB | N/A | |
| Henrik Stenqvist | Swedish Orphan Biovitrum | 55 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Annika MBA | Oncopeptides AB | 57 | |
| Anders MD | Swedish Orphan Biovitrum | 67 | |
| MSc MSc | Oncopeptides AB | 53 | |
| Christine Wesstrom | Swedish Orphan Biovitrum | 48 | |
| Johanna Flting | BioArctic AB | 51 | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| Philip Wood | Swedish Orphan Biovitrum | 55 | |
| Thomas Larsen | Swedish Orphan Biovitrum | 49 | |
| Konstantina Karampela | Swedish Orphan Biovitrum | N/A | |
| Daniel Rankin | Swedish Orphan Biovitrum | 43 | |
Management Performance
| Return On Equity | 0.0317 | |||
| Return On Asset | 0.0146 |
Camurus AB Leadership Team
Elected by the shareholders, the Camurus AB's board of directors comprises two types of representatives: Camurus AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Camurus. The board's role is to monitor Camurus AB's management team and ensure that shareholders' interests are well served. Camurus AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Camurus AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Never, Independent Director | ||
| PerAnders Abrahamsson, Independent Director | ||
| Fredrik Tiberg, President, Chief Executive Officer, Director | ||
| Fredrik Joabsson, Vice President Business Development and Alliance Management | ||
| Kerstin Strinnholm, Independent Director | ||
| Annette Mattsson, Vice President - Regulatory Affairs | ||
| Rein BSc, VP Relations | ||
| Richard Jameson, Chief Commercial Officer | ||
| Maria Lundqvist, Global HR | ||
| Agneta Svedberg, Vice President, Clinical Development & Pharmacovigilance | ||
| Behshad Sheldon, Independent Director | ||
| Torsten Malmstrom, Vice President Technical Operations | ||
| Peter Hjelmstrom, Chief Officer | ||
| Per Wallstrom, Independent Chairman of the Board | ||
| Marianne Alexandersson, Independent Director | ||
| Eva PinottiLindqvist, Chief Financial Officer | ||
| Martin Jonsson, Independent Director | ||
| Andrew McLean, VP Counsel | ||
| Jon Alonso, Chief Officer | ||
| Urban Paulsson, Vice President Corporate Development & General Counsel |
Camurus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Camurus AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0317 | |||
| Return On Asset | 0.0146 | |||
| Profit Margin | 0.03 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 14.22 B | |||
| Shares Outstanding | 55.42 M | |||
| Shares Owned By Insiders | 51.37 % | |||
| Shares Owned By Institutions | 20.61 % | |||
| Price To Earning | (34.91) X | |||
| Price To Book | 15.19 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Camurus Stock Analysis
When running Camurus AB's price analysis, check to measure Camurus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Camurus AB is operating at the current time. Most of Camurus AB's value examination focuses on studying past and present price action to predict the probability of Camurus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Camurus AB's price. Additionally, you may evaluate how the addition of Camurus AB to your portfolios can decrease your overall portfolio volatility.